A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program

BACKGROUND: Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize its use in patients in the postapproval setting, a patient registry was developed. METHODS: Data collected in an ongoing retrospective observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Redell, Mark, Moeck, Greg, Lucasti, Christopher, Durso, Stephanie, Kennedy, Cynthia, Fusaro, Karen, Loutit, Jeff, Dudley, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016411/
https://www.ncbi.nlm.nih.gov/pubmed/29977954
http://dx.doi.org/10.1093/ofid/ofy051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016411/
https://www.ncbi.nlm.nih.gov/pubmed/29977954
http://dx.doi.org/10.1093/ofid/ofy051

Ejemplares similares